AGSW(SH:600199) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-11-08 00:22Core Viewpoint - The company is transferring 92% of its subsidiary, Anhui Jintaiyang Biochemical Pharmaceutical Co., Ltd., to Shenzhen Junchen Pharmaceutical Co., Ltd. through a public listing, which has been approved by the board and shareholders [1][9]. Group 1: Transaction Overview - The transfer of the subsidiary's equity was approved in meetings held on April 28, 2024, and June 7, 2024 [1]. - The transaction does not constitute a related party transaction or a major asset restructuring [1]. - The transfer price is set at RMB 125,963,000.00, with a previous valuation indicating an increase in value of RMB 2,239.55 million, representing a 17.26% appreciation after accounting for dividend distributions [3][5]. Group 2: Financial Data and Valuation - The total assessed value of the subsidiary's equity was RMB 18,712.92 million, with a book value of RMB 16,473.37 million, resulting in a 13.59% increase [2]. - After adjusting for dividend payments, the net asset value was revised to RMB 12,973.37 million, leading to an adjusted valuation of RMB 15,212.92 million [3]. Group 3: Impact on the Company - The transaction aligns with the company's strategic goals of optimizing its asset structure and focusing on core business development [9]. - Post-transaction, the company will no longer hold any equity in the subsidiary, which is expected to enhance asset and resource utilization efficiency [9].